Evidence map›Paper›PMID 26413879›Full record

SynthesisVaccine2015

A systematic review of adverse events following immunization during pregnancy and the newborn period.

T Roice Fulton, Divya Narayanan, Jan Bonhoeffer, Justin R Ortiz, Philipp Lambach, Saad B Omer

Registry-linked trialAbstract readSystematic Review
In one paragraph

Synthesis in Vaccine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05808166 (A Phase II, Randomized, Observer-blinded, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women Between Gestational Age 14-34 Weeks and Non-Pregnant Women of 16-45 Years Old.), which is not on this map. Cited by 18 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05808166 phase2recruitingnot on this mapstarted 2024, after this paper: background citation

A Phase II, Randomized, Observer-blinded, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Hecolin® in Healthy Pregnant Women Between Gestational Age 14-34 Weeks and Non-Pregnant Women of 16-45 Years Old.

TypeinterventionalSponsorInternational Vaccine InstituteRan2024 to 2026Enrolled2,358ConditionsHepatitis E InfectionArmsHecolin® (Recombinant Hepatitis E Vaccine (Escherichia coli))., Isotonic Sodium Chloride injection
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Guideline
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Group BF1000Research · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

T Roice FultonDepartments of Global Health and Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road, Atlanta, GA 30322, USA. Electronic address: roice.fulton@gmail.com.
Divya NarayananDepartments of Global Health and Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road, Atlanta, GA 30322, USA. Electronic address: dnarayanan22@gmail.com.
Jan BonhoefferUniversity Children's Hospital (UKBB), University of Basel, Spitalstrasse 33, 4056 Basel, Switzerland; Brighton Collaboration Foundation, Spitalstrasse 33, 4056 Basel, Switzerland. Electronic address: j.bonhoeffer@brightoncollaboration.org.
Justin R OrtizInitiative for Vaccine Research, World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland. Electronic address: ortizj@who.int.
Philipp LambachInitiative for Vaccine Research, World Health Organization, Avenue Appia 20, 1211 Geneva, Switzerland. Electronic address: lambachp@who.int.
Saad B OmerDepartments of Global Health and Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road, Atlanta, GA 30322, USA; Department of Pediatrics, Emory University School of Medicine, 1648 Pierce Drive NE, Atlanta, GA 30307, USA; Emory Vaccine Center, Emory University, 201 Dowman Drive, Atlanta, GA 30322, USA. Electronic address: somer@emory.edu.

Funding

NCEZID CDC HHS U50 CK000431World Health Organization 001
6 · The paper itself

Abstract

In 2013, the WHO Strategic Advisory Group of Experts on Immunization (SAGE) requested WHO to develop a process and a plan to move the maternal immunization agenda forward in support of an increased alignment of data safety evidence, public health needs, and regulatory processes. A key challenge identified was the continued need for harmonization of maternal adverse event following immunization (AEFI) research and surveillance efforts within developing and developed country contexts. We conducted a systematic review as a preliminary step in the development of standardized AEFI definitions for use in maternal and neonatal clinical trials, post-licensure surveillance, and other vaccine studies. We documented the current extent and nature of variability in AEFI definitions and adverse event reporting among 74 maternal immunization studies, which reported a total of 240 different types of adverse events. Forty-nine studies provided explicit AEFI case definitions describing 35 separate types of AEFIs. We identified variability in how AEFIs were determined to be present, in how AEFI definitions were applied, and in the ways that AEFIs were reported. Definitions for key maternal/neonatal AEFIs differed on four discrete attributes: overall level of detail, physiological and temporal boundaries and cut-offs, severity strata, and standards used. Our findings suggest that investigators may proactively address these inconsistencies through comprehensive and consistent reporting of AEFI definitions and outcomes in future publications. In addition, efforts to develop standardized AEFI definitions should generate definitions of sufficient detail and consistency of language to avoid the ambiguities we identified in reviewed articles, while remaining practically applicable given the constraints of low-resource contexts such as limited diagnostic capacity and high patient throughput.

Indexed as

Disease Transmission, InfectiousDrug-Related Side Effects and Adverse ReactionsFemaleGlobal HealthHumansImmunizationInfant, NewbornPregnancyPregnancy Complications, InfectiousProduct Surveillance, PostmarketingVaccinesWorld Health OrganizationVaccinesAdverse eventsAEFICase definitionsmMaternal immunizationPregnancyVaccine safety

Identifiers

PMID26413879
PMCPMC8290429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.